Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 programMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex ...

Zygomatic implants represent one of the most significant advances in treatment options for seniors with severe maxillary bone loss.

Low income and high social deprivation are independently associated with adverse clinical outcomes in patients with HCM.

Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, ...

Healthcare is still organized around episodes rather than lives, and without shared governance for how data is curated, trusted and exchanged, fragmentation persists even as digital investment ...

Prof. Dr. Guido van Wingen discusses the potential of, and barriers to, the use of AI in transforming the treatment of depression ...

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAP ...

Toronto, ON - March 6, 2026 - Cloudcure, a specialized health platform dedicated to improving metabolic health through ...

Today at the Cardiovascular Research Technologies (CRT) annual conference taking place in Washington, DC, Dr. Christopher Chieh Yang Koo from National University Hospital Singapore, ...

NEW YORK, NY, UNITED STATES, March 4, 2026 /EINPresswire.com/ -- The National Association for Continuing Education ...

In veterans with type 2 diabetes, treatment with GLP-1 receptor agonists was associated with a reduced risk for various substance use disorders compared with sodium-glucose cotransporter-2, or SGLT-2, ...